WCM Soft Tissue Myoepithelial Carcinoma WGS Study (2022)
Overview
Institutional case series from Weill Cornell Medicine providing the first whole-genome sequencing (WGS) characterization of soft tissue myoepithelial carcinomas (MECs). Two male patients (ages 27 and 37) contributed 12 total tumor samples (primary plus metastatic/recurrent) profiled by WES (mean coverage 98.5x) and WGS (22–29x tumor coverage). RNA-seq was performed on one sample per patient for fusion validation. The dataset is deposited to cBioPortal as stmyec_wcm_2022.
Composition
- 2 patients with soft tissue MYEC; 12 total tumor samples.
- WES (mean 98.5x coverage) on all 12 samples; WGS on primary tumor from each patient (Patient 1: 29x tumor/25x normal; Patient 2: 22x tumor/15x normal).
- RNA-seq on one sample per patient for fusion gene validation.
- Key clinical fields: age at diagnosis, sex, primary vs metastatic/recurrent sample designation, SMARCB1 and SMARCA2 IHC status.
Assays / panels (linked)
- whole-exome-seq — all 12 samples, mean 98.5x coverage
- whole-genome-seq — primary tumor from each patient, 22–29x
- rna-seq — one sample per patient for fusion validation
- FISH — confirmatory EWSR1 rearrangement testing
Papers using this cohort
- PMID:36577525 — Cyrta et al., Cold Spring Harbor Molecular Case Studies 2022. Whole-genome characterization of myoepithelial carcinomas of the soft tissue.
Notable findings derived from this cohort
- Both MECs displayed very low tumor mutation burden (mean 1.35 mutations/Mb, range 0.43–2.98), consistent with fusion-driven oncogenesis and absence of targetable point mutations by WES PMID:36577525.
- Patient 1 harbored a novel ASCC2::GGNBP2 in-frame fusion, homozygous SMARCB1 deletion, and biallelic NF1 loss, all arising from a single >30-way biallelic chromoplexy event involving chromosomes 17, 19, and 22 — detectable only by WGS PMID:36577525.
- Patient 2 harbored an EWSR1::KLF15 rearrangement and high-level (>10 copy) ELK4 amplification via double minute, also identified by WGS PMID:36577525.
- COSMIC Signature 3 (HR-deficiency-associated) contributed 36.8% and 17.4% of SNVs in MEC1 and MEC2 respectively, despite no detectable somatic HR pathway alterations PMID:36577525.
Sources
- cBioPortal study:
stmyec_wcm_2022 - Associated publication: PMID:36577525
This page was processed by crosslinker on 2026-05-05.